Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Paul R. Sieber"'
Autor:
Johanna C. Bendell, Boris Kin Lin, Sophie Callies, Anna M. Szpurka, Gregory P. Donoho, Volker Wacheck, Wei Zhang, Susan C. Guba, Paul R. Sieber, Neal D. Shore, Costantine Albany, Ian D. Schnadig, David S. Morris, Oscar B. Goodman, Bryan A. Mehlhaff, Jennifer L. Cultrera, Sunil Babu, Ivor J. Percent, Christopher J. Sweeney
Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::224daf568721c80e465b0dae93e74292
https://doi.org/10.1158/1078-0432.22482390.v1
https://doi.org/10.1158/1078-0432.22482390.v1
Autor:
Johanna C. Bendell, Boris Kin Lin, Sophie Callies, Anna M. Szpurka, Gregory P. Donoho, Volker Wacheck, Wei Zhang, Susan C. Guba, Paul R. Sieber, Neal D. Shore, Costantine Albany, Ian D. Schnadig, David S. Morris, Oscar B. Goodman, Bryan A. Mehlhaff, Jennifer L. Cultrera, Sunil Babu, Ivor J. Percent, Christopher J. Sweeney
Purpose:To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) following cancer progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a955fdf62bcabf4dd78a334c5904c2c
https://doi.org/10.1158/1078-0432.c.6530910
https://doi.org/10.1158/1078-0432.c.6530910
Autor:
Christopher J. Sweeney, Ivor J. Percent, Sunil Babu, Jennifer L. Cultrera, Bryan A. Mehlhaff, Oscar B. Goodman, David S. Morris, Ian D. Schnadig, Costantine Albany, Neal D. Shore, Paul R. Sieber, Susan C. Guba, Wei Zhang, Volker Wacheck, Gregory P. Donoho, Anna M. Szpurka, Sophie Callies, Boris Kin Lin, Johanna C. Bendell
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(11)
Purpose: To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) following cancer progressio
Publikováno v:
Journal of Urology. 171:2272-2276
We evaluated changes in bone mineral density (BMD), fat-free mass (FFM) and serum lipid levels during bicalutamide 150 mg monotherapy compared with medical castration for 2 years.A total of 103 men with localized or locally advanced prostate cancer (
Autor:
Paul R, Sieber
Publikováno v:
Reviews in urology. 16(1)
Prostate cancer is the most prevalent cancer in US and European men and the second leading cause of cancer death in those populations. It is somewhat unique in that nearly all patients who succumb to the disease will ultimately develop bone metastasi
Publikováno v:
The American Journal of Dermatopathology. 29:300-302
Infection from Histoplasma capsulatum is usually subclinical, but it also can be disseminated in patients with a compromised immune status. Involvement of the external genitalia is a rare finding, occurring by direct contact or hematogenous spread. W
Autor:
Paul R Sieber
Publikováno v:
Expert review of anticancer therapy. 7(12)
Bicalutamide is a competitive nonsteroidal androgen receptor antagonist. In the European Union and a number of other countries, bicalutamide 150 mg per day is approved as an adjuvant to primary treatments (radical prostatectomy or radiotherapy) or as
Autor:
Paul R. Sieber, J. Moteff
Publikováno v:
Metallurgical transactions. 5:315-317
Autor:
Paul R. Sieber
Publikováno v:
Annals of surgery. 67(1)